Australia has recorded its second case of blood clotting likely linked to the AstraZeneca COVID-19 vaccine.
A Western Australian woman in her 40s suffered the rare reaction after receiving the shot recently.
The woman is in hospital receiving treatment and is in a stable condition.
LIVE UPDATES: International travel may not return to pre-pandemic levels until 2024
READ MORE: Man dies of COVID-19 in Queensland
The Therapeutic Goods Administration (TGA) confirmed the medical event was linked to the AstraZeneca dose.
The Australian Technical Advisory Group on Immunisation (ATAGI) recently issued updated advice recommending that the AstraZeneca jab be reserved for those over the age of 50, due to a rare but serious side effect of a blood clotting disorder.
Australians under 50 can still elect to receive the AstraZeneca vaccine if they chose, with experts noting the risk remained remote.
https://twitter.com/cokeefe9/status/1381787107924975619READ MORE: Chinese vaccines 'don't have very high protection rates'
Leading Australian epidemiologist Professor Nancy Baxter said on the weekend the risk was lower compared to potential adverse reactions to other medications.
"It's uncommon - about 1 in 100,000 to one in 200,000 people - meaning that 99,999 people who get the AstraZeneca vaccine do not have a problem," she said.
Around one-quarter of those who develop the blood clotting reaction will die.
READ MORE: Pfizer rollout made easier as vials 'very stable' at -20C
The European Medicines Agency is conducting reviews into both the AstraZeneca and Johnson & Johnson vaccines following cases of blood clots.
However, health advice in Australia has been for the government to proceed with the rollout - albeit with the added caveat that AstraZeneca is best reserved for people over 50.
from 9News https://ift.tt/3tjYqvy
via IFTTT
0 Comments